A biotech early stage investment firm invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.
The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.
The firm does not have any specific requirements for companies and their management teams. Th firm can act as a lead or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
A venture capital firm based in the USA is currently investing from their second fund. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.
The firm invests in medical device, diagnostics, and digital health companies. The firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.
The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
RESI London, held in person on December 4 at 11 Cavendish Square in London, followed by two-days of virtual partnering on December 5-6, and RESI JPM, taking place in San Francisco on January 13 at the Marriott Marquis, followed by three days of virtual partnering January 14-15 and January 21, offer unparalleled opportunities to connect with global investors. The partnering platform for both events opens on Monday, November 18, providing attendees with options to book both in-person and virtual meetings. Through the LSN Partnering Platform, startups can identify investors suited to their needs by sector, indication, stage of development, and other key criteria. Successful partnering takes preparation, with top companies typically sending over 100 meeting requests to relevant investors and following up frequently to secure impactful connections. Next week, we will be offering a free partnering tutorial to help you maximize your RESI London experience, and another in December focused on RESI JPM.
Free Partnering Tutorial Webinars
Understanding the RESI partnering system and using it to its maximum capabilities can greatly impact a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are the best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.
November 12 – 10AM ET: Partnering Tutorial (RESI London) – Sign up
December 3 – 12PM ET: Partnering Tutorial (RESI JPM) – Sign up
In this interview, we sit down with Diana Caldwell, CEO of Amplified Sciences and the first-place winner of the Innovator’s Pitch Challenge (IPC) at RESI Boston. Amplified Sciences stood out with their innovative approach, impressing both judges and attendees. Today, Diana shares insights into her company’s journey, their groundbreaking technology, and the experience of pitching at RESI. Join us as we dive into the story behind Amplified Sciences and what this win means for their future.
Interested in showcasing your innovation? Applications for the Innovator’s Pitch Challenge at RESI London and RESI JPM are open until this Friday, November 8th. Don’t miss the opportunity to pitch in front of a dedicated panel of investors, gain valuable feedback, and make lasting connections. Apply now to take your innovation to the next level.
By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
RESI JPM will take place at the Marriott Marquis in San Francisco during the JPM conference week. This conference provides a comprehensive in-person experience on January 14, where service providers can connect directly with early-stage life science and healthcare companies and investors. RESI offers a valuable opportunity for exhibitors, including CROs, CMOs, banks, and law and consultant firms to network with startups that are actively seeking partnerships for development and growth.
Eva Garland Consulting (EGC), a consultant firm specializing in grant proposal preparation and strategies was an exhibitor at RESI Boston. Review their shared insights in the video testimonial which highlights the unique networking opportunities and targeted connections that RESI offers.
RESI’s commitment to early-stage companies gives service providers a specialized platform to reach ideal clients in life sciences. CROs and CMOs have the chance to connect with preclinical therapeutics, labs with R&D space can meet startups in need of facilities, consultant firms provide strategy for grants, regulatory, as well as other areas, and life science-specific banks and law firms specializing in IP and term sheet negotiations can connect with founders seeking these services.
The RESI exhibition package includes a table for promotion and networking in the exhibit hall, along with prominent logo placement on the RESI website, program guide, and onsite signage. Exhibitors also receive complimentary registration to participate in the partnering platform and attend all conference events, maximizing their visibility and networking potential. Interested in reaching a broad audience of early-stage entrepreneurs at RESI JPM? Contact us at resi@lifesciencenation.com to learn more!
Participants will now enjoy a 6-minute presentation followed by a 7-minute Q&A session with sector-specific investor judges. Additionally, each company will have access to table and poster space (excluding RESI London) and a standard 3-day ticket for both in-person and virtual partnering. This extended format allows companies to provide a more comprehensive overview of their investment readiness and engage in deeper discussions with potential investors.
Upcoming Events
RESI London 2024, December 4 (In-person); 5-6 (Virtual Partnering Only)
RESI JPM 2025, January 14 (In-person); 15-16 (Virtual Partnering Only)
Due to limited pitch slots, we encourage you to apply early.
For questions or to apply, please reach out to our team at salescore@lifesciencenation.com. Don’t miss this opportunity to showcase your innovations and connect with potential investors!
The upcoming Redefining Early Stage Investments (RESI) Conference in London is shaping up to be a remarkable event for life science innovators worldwide. The conference will be taking place in-person on December 4 at 11 Cavendish Square, followed by virtual partnering on December 5-6. RESI London 2024 is set to connect ambitious life science start-ups with a diverse array of early-stage investors and strategic partners from across the globe.
Featured RESI London Investors
RESI’s reach goes well beyond the UK. While London-based investors like Delin Ventures, Boost Capital Partners, and Calculus Capital will be actively participating, RESI London 2024 will also welcome an extensive lineup of international firms, opening doors to far-reaching networks and growth opportunities.
European representation will be especially strong. In addition to local players, leading firms such as M Ventures from The Netherlands and CVX Ventures from Denmark will be present, providing crucial European connections for attending start-ups.
But the participation doesn’t stop at Europe. From the United States, esteemed investors like Optum Ventures and Lifespan Vision Ventures will take part in the event. Expanding beyond the Eastern Hemisphere, attendees can connect with firms such as Teijin Pharma from Japan, and Brandon Capital Partners from Australia, all of whom are eager to explore new partnerships with innovative life science start-ups.
RESI London 2024 offers an unparalleled chance to engage with a diverse and globally-minded group of investors. Interested in joining? Contact us at resi@lifesciencenation.com or click here to learn more.
Diana Caldwell
Next Phase Newsletter 